|Drug class||NMDA receptor modulator|
AGN-241751 is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD). It was originated by Naurex and was acquired by Allergan from Aptinyx in May 2018. Allergan (previously Naurex) is also developing the NMDA receptor modulators rapastinel (GLYX-13; intravenous) and apimostinel (NRX-1074, AGN-241660; oral) for the treatment of MDD. Like apimostinel, AGN-241751 is intended as an oral follow-up compound to rapastinel. As of May 2018, the drug is in phase I clinical trials.
- "Research programme: NMDA receptor modulators - Allergan - AdisInsight". adisinsight.springer.com.
- Inc., Aptinyx. "Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration". www.prnewswire.com.
- Vazquez GH, Camino S, Tondo L, Baldessarini RJ (2017). "Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics". CNS Neurol Disord Drug Targets. 16 (8): 858–869. doi:10.2174/1871527316666170728165648. PMID 28758582.
- "Rapastinel - Allergan - AdisInsight". adisinsight.springer.com.
- "Apimostinel - Allergan - AdisInsight". adisinsight.springer.com.
- "J&J therapy for suicidal depressives 'a breakthrough', says FDA". PMLive. 17 August 2016.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|